Stay updated on SBRT and FAK Inhibitor in Advanced Pancreas Adenocarcinoma Clinical Trial
Sign up to get notified when there's something new on the SBRT and FAK Inhibitor in Advanced Pancreas Adenocarcinoma Clinical Trial page.

Latest updates to the SBRT and FAK Inhibitor in Advanced Pancreas Adenocarcinoma Clinical Trial page
- Check4 days agoChange DetectedRevision note updated from v3.5.0 to v3.5.2.SummaryDifference0.1%

- Check11 days agoNo Change Detected
- Check18 days agoNo Change Detected
- Check25 days agoChange DetectedUpdated the follow-up time frame for several outcomes. The period from 91 days through completion of follow-up (estimated 24 months) was replaced with 91 days through 12 months post-SBRT or 90 days after the last defactinib dose, whichever comes first (estimated 12 months 5 days).SummaryDifference0.3%

- Check32 days agoChange DetectedPage revision updated from v3.4.3 to v3.5.0.SummaryDifference0.1%

- Check39 days agoChange DetectedRevision label updated from v3.4.2 to v3.4.3 on the page.SummaryDifference0.1%

- Check61 days agoChange DetectedAdministrative updates to the study record show revised start and completion dates and a new last-update timestamp. The updated timeline reflects changes to the trial's schedule.SummaryDifference0.4%

- Check68 days agoChange DetectedAdded Revision: v3.4.2; removed prior notices about government funding lapse and operating status, with no impact on study details or core content. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

Stay in the know with updates to SBRT and FAK Inhibitor in Advanced Pancreas Adenocarcinoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the SBRT and FAK Inhibitor in Advanced Pancreas Adenocarcinoma Clinical Trial page.